Archive | Clinical Trials

Pembrolizumab Plus Reduced-dose Ipilimumab Safe in Advanced Melanoma

Patients with advanced melanoma may have good outcomes when treated with standard-dose pembrolizumab with 4 doses of reduced-dose ipilimumab, according to a study published in The Lancet Oncology.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Personalized Cancer Vaccines Demonstrate Potential in Melanoma Studies

NEW YORK (GenomeWeb) – A pair of new studies is pointing to the potential of personalized anti-cancer vaccine strategies in individuals with advanced melanoma.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Nivolumab extends survival in resected, high-risk melanoma

Nivolumab prolonged RFS compared with ipilimumab among patients with advanced melanoma who had undergone resection, according to an interim analysis of a randomized phase 3 trial.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Nivolumab Does Not Prolong Overall Survival in Advanced Melanoma

Nivolumab, a monoclonal antibody targeting PD-1, does not improve overall survival (OS) among patients with advanced melanoma whose disease progresses after receiving ipilimumab, according to a study published in the Journal of Clinical Oncology.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories